Anti‐TGF‐β antibody blocks enamel matrix derivative‐induced upregulation of p21WAF1/cip1 and prevents its inhibition of human oral epithelial cell proliferation
Authors:
- 1 August 2002
- journal article
- research article
- Published by Wiley in Journal of Periodontal Research
- Vol. 37 (4) , 255-262
Abstract
We have previously demonstrated that porcine enamel matrix derivative (EMD) contains TGF‐β1 (or a TGF‐β‐like substance), and that EMD rapidly translocates smad2, which is an effector of the TGF‐β signaling pathway, into the nucleus and modulates the proliferation of both human gingival fibroblastic and oral epithelial cells in a cell type‐specific manner. To investigate the involvement of TGF‐β in the growth modulatory action of EMD, two approaches have been used in the present study: i) a neutralizing anti‐TGF‐β antibody to block EMD action, and ii) authentic porcine TGF‐β1 to compare with EMD. Both in epithelial and fibroblastic cells, TGF‐β1 closely mimicked EMD in nuclear accumulation of smad2, phosphorylation of MAP kinase family members, and consequent cell type‐specific growth modulation. Anti‐TGF‐β antibody, at levels which completely blocked TGF‐β1‐induced smad2 translocation, strongly blocked EMD‐induced smad2 translocation. This antibody also blocked other actions of EMD in epithelial cells, i.e. p38‐MAP kinase (p38‐K) phosphorylation, p21WAF1/cip1 expression, and inhibition of DNA synthesis. In support of our previousproposal,thesedatasuggest that TGF‐β1 (or a TGF‐β‐like substance), which is delivered as a principal bio‐active factor in EMD, inhibits epithelial cell proliferation probably by a smad2‐mediated, p21WAF1/cip1‐dependent mechanism. However, the same neutralizing antibody failed to convincingly block EMD‐induced fibroblastic proliferation, which suggests that EMD may contain additional unidentified mitogenic factor(s), which act in combination with TGF‐β to fully stimulate fibroblastic proliferation.Keywords
This publication has 17 references indexed in Scilit:
- Levels of tissue inhibitor of metalloproteinases‐1 and matrix metalloproteinases‐1 and ‐8 in gingival crevicular fluid following treatment with enamel matrix derivative (EMDOGAIN®)Journal of Periodontal Research, 2001
- Enamel Matrix Derivative in the Treatment of Human Intrabony Osseous DefectsJournal of Periodontology, 2000
- Histologic Evaluation of Periodontal Healing in Humans Following Regenerative Therapy With Enamel Matrix Derivative. A 10‐Case SeriesJournal of Periodontology, 2000
- Periodontal tissue alterations following Emdogain® treatment of periodontal sites with angular bone defects.Journal of Clinical Periodontology, 1999
- The use of barrier membranes and enamel matriz proteins in the treatment of angular bone defects. A prospective controlled clinical trial.Journal of Clinical Periodontology, 1999
- Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regenerationJournal of Periodontal Research, 1999
- Comparison of Enamel Matrix Proteins and Bioabsorbable Membranes in the Treatment of Intrabony Periodontal Defects. A Split‐Mouth StudyJournal of Periodontology, 1999
- Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects.Journal of Clinical Periodontology, 1997
- Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins.Journal of Clinical Periodontology, 1997
- Clinical safety of enamel matrix derivative (EMDOGAIN®) in the treatment of periodontal defectsJournal of Clinical Periodontology, 1997